UK SACT Board publication: Guidance on the contents of a SACT protocol

 

Dear Colleague,

 

Please find a link to the updated publication, “Guidance for the Content of SACT Protocol,” available here: https://www.uksactboard.org/publications.

 

This document has been developed to support all organisations when writing protocols and will form a baseline for the UK National SACT Protocol pilot project starting later this year.

 

We would like to extend our sincere thanks to everyone involved in the development and review of this guidance. Your expertise, input, and dedication have been invaluable in creating a robust and practical resource for all cancer healthcare professionals.

 

Kind Regards,

Netty Cracknell and Joe Williams

Co-Chairs UK SACT Board

On behalf of the UK SACT Board

https://www.uksactboard.org/

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article